Health
Platform to predict future AF/atrial flutter nets breakthrough device designation – Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter,…
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected] to Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter, developed in collaboration with Geisinger.
The platform (Tempus ECG Analysis Platform, Tempus and Geisinger) is designated for use in patients aged 40 years and older who do not…
-
Noosa News15 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News15 hours agoMotorcyclist dies in crash with truck
-
Noosa News16 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General21 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging